Viking Therapeutics Inc.

4.04-0.0900-2.18%Vol 115.25K1Y Perf -21.00%
Dec 2nd, 2022 10:45 DELAYED
BID4.04 ASK4.05
Open4.08 Previous Close4.13
Pre-Market4.07 After-Market-
 -0.06 -1.45%  - -
Target Price
16.00 
Analyst Rating
Strong Buy 1.13
Potential %
293.53 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
59.06 
Earnings Rating
Sell
Market Cap309.82M 
Earnings Date
26th Oct 2022
Alpha0.03 Standard Deviation0.27
Beta1.44 

Today's Price Range

4.014.10

52W Range

2.025.44

5 Year PE Ratio Range

-15.40-4.50

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
2.24%
1 Month
-4.43%
3 Months
29.34%
6 Months
83.86%
1 Year
-21.00%
3 Years
-42.42%
5 Years
35.76%
10 Years
-

TickerPriceChg.Chg.%
VKTX4.04-0.0900-2.18
AAPL146.35-1.9600-1.32
GOOG100.05-1.2300-1.21
MSFT252.04-2.6500-1.04
XOM110.850.05000.05
WFC45.19-1.6755-3.57
JNJ177.19-1.5500-0.87
FB196.640.99000.51
GE85.470.21000.25
JPM134.21-2.0300-1.49
 
Earnings HistoryEstimateReportedSurprise %
Q03 2022-0.23-0.218.70
Q02 2022-0.21-0.23-9.52
Q01 2022-0.20-0.21-5.00
Q04 2021-0.19-0.1615.79
Q03 2021-0.21-0.1719.05
Q02 2021-0.19-0.20-5.26
Q01 2021-0.18-0.19-5.56
Q04 2020-0.15-0.150.00
Earnings Per EndEstimateRevision %Trend
12/2022 QR-0.238.00Positive
12/2022 FY-0.884.35Positive
3/2023 QR-0.247.69Positive
12/2023 FY-0.9812.50Positive
Next Report Date-
Estimated EPS Next Report-0.23
Estimates Count7
EPS Growth Next 5 Years %-
Volume Overview
Volume115.25K
Shares Outstanding76.69K
Shares Float75.22M
Trades Count1.05K
Dollar Volume467.72K
Avg. Volume650.87K
Avg. Weekly Volume401.73K
Avg. Monthly Volume798.29K
Avg. Quarterly Volume752.60K

Viking Therapeutics Inc. (NASDAQ: VKTX) stock closed at 4.13 per share at the end of the most recent trading day (a 1.23% change compared to the prior day closing price) with a volume of 270.16K shares and market capitalization of 309.82M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 20 people. Viking Therapeutics Inc. CEO is Brian Lian.

The one-year performance of Viking Therapeutics Inc. stock is -21%, while year-to-date (YTD) performance is -10.87%. VKTX stock has a five-year performance of 35.76%. Its 52-week range is between 2.02 and 5.44, which gives VKTX stock a 52-week price range ratio of 59.06%

Viking Therapeutics Inc. currently has a PE ratio of -5.00, a price-to-book (PB) ratio of 2.03, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -31.53%, a ROC of -34.24% and a ROE of -33.84%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Viking Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.23 for the next earnings report. Viking Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Viking Therapeutics Inc. is Strong Buy (1.13), with a target price of $16, which is +293.53% compared to the current price. The earnings rating for Viking Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Viking Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Viking Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 17.50, ATR14 : 0.23, CCI20 : -38.85, Chaikin Money Flow : -0.23, MACD : 0.06, Money Flow Index : 44.37, ROC : -4.62, RSI : 55.04, STOCH (14,3) : 34.59, STOCH RSI : 1.00, UO : 49.30, Williams %R : -65.41), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Viking Therapeutics Inc. in the last 12-months were: Matthew W. Foehr (Buy at a value of $111 195)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (87.50 %)
7 (87.50 %)
7 (87.50 %)
Moderate Buy
1 (12.50 %)
1 (12.50 %)
1 (12.50 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.13
Strong Buy
1.13
Strong Buy
1.13

Viking Therapeutics Inc.

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

CEO: Brian Lian

Telephone: +1 858 704-4660

Address: 12340 El Camino Real, San Diego 92130, CA, US

Number of employees: 20

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

51%49%

Bearish Bullish

51%49%

TipRanks News for VKTX

Fri, 28 Oct 2022 11:50 GMT Analysts Are Bullish on Top Healthcare Stocks: Viking Therapeutics (VKTX), Sanofi (SNYNF)

- TipRanks. All rights reserved.

Fri, 29 Jul 2022 11:56 GMT Viking Therapeutics (VKTX) Receives a Buy from Maxim Group

- TipRanks. All rights reserved.

Wed, 20 Jul 2022 16:25 GMT Analysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), Hookipa Pharma (HOOK)

- TipRanks. All rights reserved.

Wed, 20 Jul 2022 08:25 GMT Analysts Are Bullish on Top Healthcare Stocks: Viking Therapeutics (VKTX), Eledon Pharmaceuticals (ELDN)

- TipRanks. All rights reserved.

News

Stocktwits